Bionano Genomics, Inc. (BNGO)
NASDAQ: BNGO · Real-Time Price · USD
1.190
+0.020 (1.71%)
Jun 9, 2026, 1:15 PM EDT - Market open
Bionano Genomics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -31.6 | -26.4 | -112.02 | -232.49 | -132.6 | -72.44 |
Depreciation & Amortization | 9.61 | 9.73 | 14.23 | 13.91 | 9.84 | 3.37 |
Stock-Based Compensation | 3.62 | 4.53 | 9.74 | 15.18 | 22.42 | 9.72 |
Other Adjustments | 1.21 | -4.73 | 14.98 | 92.99 | 3.46 | -4.93 |
Change in Receivables | -0.78 | -0.45 | 4.14 | -2.3 | -2.25 | -0.49 |
Changes in Inventories | 3.7 | 4.92 | -0.59 | -4.15 | -23.68 | -15.93 |
Changes in Accounts Payable | -1.5 | -1.37 | -3.42 | -2 | 1.95 | 6.78 |
Changes in Accrued Expenses | -1.51 | -0.58 | -2.24 | -2.52 | 0.37 | 3.96 |
Changes in Other Operating Activities | -2.05 | -2 | 6.26 | -3.81 | -4.33 | -1.97 |
Operating Cash Flow | -19.3 | -16.35 | -68.92 | -125.18 | -124.82 | -71.93 |
Capital Expenditures | - | - | -0.1 | -1.69 | -3.2 | -1.46 |
Sale of Property, Plant & Equipment | - | - | - | - | 0.03 | - |
Purchases of Intangible Assets | - | - | - | - | -0.1 | - |
Purchases of Investments | -225.78 | -241.88 | -233.02 | -111.26 | -84.2 | -313.39 |
Proceeds from Sale of Investments | 232.56 | 229.13 | 306.96 | 137.02 | 200.89 | 86.48 |
Payments for Business Acquisitions | - | - | - | - | -31.34 | -49.09 |
Proceeds from Business Divestments | - | - | - | 0.1 | 0.69 | - |
Other Investing Activities | - | - | - | - | - | -0.61 |
Investing Cash Flow | 6.78 | -12.75 | 73.84 | 24.16 | 82.77 | -278.06 |
Long-Term Debt Issued | - | - | 16.25 | 75.48 | - | - |
Long-Term Debt Repaid | -3.45 | -4.95 | -71.43 | -9.05 | -0.04 | -15.01 |
Net Long-Term Debt Issued (Repaid) | -3.45 | -4.95 | -55.18 | 66.43 | -0.04 | -15.01 |
Issuance of Common Stock | 17.26 | 28.99 | 41.5 | 56.38 | 23.04 | 351.12 |
Net Common Stock Issued (Repurchased) | 17.26 | 28.99 | 41.5 | 56.38 | 23.04 | 351.12 |
Other Financing Activities | - | - | - | -9 | - | - |
Financing Cash Flow | 13.81 | 24.04 | -13.69 | 113.82 | 23.01 | 336.11 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0 | -0.01 | -0.01 | 0.07 | -0.04 | - |
Net Cash Flow | 1.29 | -5.06 | -8.78 | 12.86 | -19.08 | -13.88 |
Free Cash Flow | -19.3 | -16.35 | -69.03 | -126.87 | -128.02 | -73.39 |
FCF Margin | -67.15% | -57.33% | -224.28% | -351.29% | -460.46% | -408.14% |
Free Cash Flow Per Share | -0.01 | -3.00 | -54.31 | -222.97 | -265.58 | -159.09 |
Levered Free Cash Flow | -26.8 | -20.65 | -153.06 | -166.31 | -151.68 | -92.69 |
Unlevered Free Cash Flow | -24.59 | -22.73 | -89.87 | -215.56 | -152.64 | -76.71 |